![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
![]() | |
![]() | |
Native name | エーザイ株式会社 |
---|---|
Romanized name | Ēzai kabushiki gaisha |
Company type | Public KK |
TYO: 4523 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component | |
Industry | Pharmaceuticals |
Founded | December 6, 1941 |
Founder | Toyoji Naito |
Headquarters | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan |
Key people | Haruo Naito (President and CEO) |
Products | |
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Owner | The Master Trust Bank of Japan (11.78%) Japan Trustee Services Bank (10.99%) Nippon Life (4.29%)[2] |
Number of employees | ![]() |
Website | Official website |
Footnotes / references [2] [1] |
Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[3]